Hemab Therapeutics Holdings, Inc.
COAGNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $1.05B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $23.00$55.42
- Volume (live)
- -
- Avg. volume (3M)
- 547.84K
Hemab Therapeutics Holdings (COAG) Stock Price & Financial Analysis
Hemab Therapeutics Holdings Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $34.44 - $35.90 |
|---|---|
| 52-Week High | $55.42 |
| 52-Week Low | $23.00 |
| Open | $35.20 |
| Volume (last close) | 368.98K |
| Average Volume (3M) | 547.84K |
| 50-Day MA | $40.32 |
|---|
| Market Cap | 1.05B |
|---|---|
| Shares Outstanding | 30.11M |
| Price to Book (P/B) | 2.31 |
| EV/EBITDA | -9.92 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Hemab Therapeutics Holdings at a Glance
As of the Oct 22, 2026 close, Hemab Therapeutics Holdings (COAG) has a market capitalization of $1.05B.
As of its latest reported balance sheet, it holds $237.37M in cash and securities against $1.03M of debt, a net cash position of $236.34M.
Hemab Therapeutics Holdings does not currently pay a dividend.
At $34.86 (the Oct 22, 2026 close) it sits within its 52-week range of $23.00 to $55.42.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $62.50, 79.3% above the Oct 22, 2026 close.
Frequently Asked Questions About Hemab Therapeutics Holdings
What is the current stock price for COAG?
As of the Oct 22, 2026 close, COAG stock trades at $34.86. The 52-week range is $23.00–$55.42, with a day range of $34.44–$35.90.
What is the P/E ratio for COAG?
The P/E ratio (Price-to-Earnings) for COAG is shown in the Key Statistics section. This valuation metric helps compare Hemab Therapeutics Holdings, Inc. to industry peers.
Does COAG pay dividends?
Hemab Therapeutics Holdings does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for COAG?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for COAG is Buy. The average 12-month price target is $62.50, a 79.3% upside from the Oct 22, 2026 close of $34.86.
What is the market cap of COAG?
As of the Oct 22, 2026 close, Hemab Therapeutics Holdings's market capitalization is $1.05B, classifying it as a small-cap company. Hemab Therapeutics Holdings operates in the Healthcare sector within the Biotechnology industry.